Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 11/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.31 |
| ▸ | LIMK2 | P53671 | 2/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4125954 | 0.93 | PTGS2 (0.35) | NAMPTKMT2APTGS2HTR2AHTR2C | |
| SCHEMBL3704890 | 0.91 | P2RX7 (0.34) | NAMPTKMT2APTGS2HTR2AHTR2C | |
| SCHEMBL4130773 | 0.91 | ALDH1A1 (0.37) | NAMPTKMT2AHTR2AHTR2CKCNH2 | |
| SCHEMBL3698449 | 0.91 | NR2F2 (0.35) | NAMPTPTGS2HTR2AHTR2CKCNH2 | |
| SCHEMBL4118130 | 0.88 | NAMPT (0.39) | NAMPTKMT2APTGDR2 | |
| SCHEMBL3700227 | 0.86 | NAMPT (0.32) | NAMPTPTGS2LIMK2 | |
| SCHEMBL4130428 | 0.86 | SLC16A3 (0.34) | NAMPTPTGS2HTR2AHTR2CKCNH2 | |
| SCHEMBL4125819 | 0.85 | PTGS2 (0.33) | NAMPTPTGS2HTR2AHTR2CKCNH2 | |
| SCHEMBL3709941 | 0.85 | PTGS2 (0.33) | NAMPTPTGS2 | |
| SCHEMBL4131057 | 0.85 | PTGS2 (0.33) | NAMPTPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | NAMPT 2129/4885KMT2A 4776/4885PTGS2 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.